Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Quality by Design-driven Analytical Method: A Quality Risk Management-Based Liquid Chromatography Method for Daclatasvir and Characterization of its Putative Degradants by LC-MS/MS

Author(s): Prashant Chaturvedi, Shruti Chopra*, Kalyani Joshi and Savita Tauro

Volume 20, Issue 3, 2024

Published on: 29 April, 2024

Page: [188 - 201] Pages: 14

DOI: 10.2174/0115734129285465240408044841

Price: $65

conference banner
Abstract

Background: Antiviral drugs can cure more than 95 percent of people with hepatitis C, but the inaccessibility of quality affordable medicines and the lack of their uninterrupted supply poses a major challenge. Impurities in drugs have a significant impact on their quality and are one of the substantial causes of drug recalls, ultimately leading to the unavailability of the drug in the market. Hence, there is a need for a robust, quality risk management and quality by design-driven analytical method that can detect the antiviral drug, Daclatasvir dihydrochloride, in the presence of its probable impurities.

Objective: This study aimed to develop a Quality by Design-driven stability- indicating liquid chromatography method for Daclatasvir dihydrochloride and the characterization of its putative degradants by LC-MS.

Method: The fishbone diagram and quality risk assessment investigated twenty-four process parameters and concluded that three risk parameters, i.e., flow rate, buffer pH, and stationary phase type, were the critical process parameters. The critical quality attributes viz. resolution between impurity 6 and DCV and impurity 2 & 3 (Rs˃1.5), the shape of the peak of DCV which is decided by the Number of Theoretical Plates (NTP˃5000), and the retention time of Daclatasvir (tR14-23 mins) were optimized using a two-level three-factor full factorial design with five center points.

Results: The optimized method is stability-indicating in its true sense as it can separate the sample with its degradants generated in basic (three), acidic (two), oxidative (H2O2: three, Azobisisobutyronitrile: one), photo (three), and dry heat (one) conditions. Degradants structures were elucidated, and degradation routes were established, using LC-MS and LC-MS/MS analyses.

Conclusion: The drug is highly susceptible to acid, base hydrolysis, and oxidation degradation conditions and poses a significant risk to the analytical method to fail in system suitability criteria. Hence, a robust and flexible chromatographic method with the capacity for continuous improvement was developed and successfully validated within the criteria of design space.

Keywords: Quality by Design (QbD), Critical Quality Attributes (CQA), Critical Process Parameters (CPPs), Quality Risk Management (QRM), Design of Experiment (DoE), Daclatasvir Dihydrochloride (DCV), LC-MS/MS.

« Previous Next »
Graphical Abstract

[1]
Gamal, N.; Gitto, S.; Andreone, P. Efficacy and safety of daclatasvir in Hepatitis C: An overview. J. Clin. Transl. Hepatol., 2016, 4(4), 336-344.
[PMID: 28097103]
[2]
WHO. World Hepatitis Day 2021: Hepatitis can’t wait!, 2021. Available From: https://www.who.int/europe/news-room/events/item/2021/07/28/default-calendar/world-hepatitis-day-2021--hepatitis-can-t-wait!
[3]
WHO. Update on nitrosamine impurities., 2019. Available From: https://www.who.int/news/item/20-11-2019-information-note-nitrosamine-impurities
[4]
FDA. Control of nitrosamine impurities in human drugs., 2020. Available From: https://www.fda.gov/media/141720/download
[5]
Bharate, S.S. Critical analysis of drug product recalls due to nitrosamine impurities. J. Med. Chem., 2021, 64(6), 2923-2936.
[http://dx.doi.org/10.1021/acs.jmedchem.0c02120] [PMID: 33706513]
[6]
Tuesuwan, B.; Vongsutilers, V. Nitrosamine contamination in pharmaceuticals: Threat, impact, and control. J. Pharm. Sci., 2021, 110(9), 3118-3128.
[http://dx.doi.org/10.1016/j.xphs.2021.04.021] [PMID: 33989680]
[7]
Mirasol, F. Pharma industry contends with contamination-based recalls. Pharmaceut. Technol., 2021, 2021(2), s32-s34.
[8]
Verch, T.; Campa, C.; Chéry, C.C.; Frenkel, R.; Graul, T.; Jaya, N.; Nakhle, B.; Springall, J.; Starkey, J.; Wypych, J.; Ranheim, T. Analytical quality by design, life cycle management, and method control. AAPS J., 2022, 24(1), 34.
[http://dx.doi.org/10.1208/s12248-022-00685-2] [PMID: 35149913]
[9]
The European Medicines Agency. ICH Harmonised Tripartite Guideline Pharmaceutical Development Q8 (R2)., 2009. Available from: https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf
[10]
The European Medicines Agency. ICH Harmonised Tripartite Guideline Quality Risk Management Q9. 2005. Available From: https://www.ema.europa.eu/en/documents/scientificguideline/ international-conference-harmonisation-technicalrequirements- registration-pharmaceuticals-human-use-ichguideline- q9-quality-risk-management-step-5-first-version_en.pdf
[11]
The European Medicines Agency. ICH Harmonised Tripartite Guideline Pharmaceutical Quality System Q10., 2008. Available From: https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-guideline-q10-pharmaceutical-quality-system-step-5_en.pdf
[12]
The European Medicines Agency. ICH Q14 Analytical procedure development - Scientific guideline., 2022. Available From: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q14-guideline-analytical-procedure-development-step-5_en.pdf
[13]
Huang, J.; You, J.X.; Liu, H.C.; Song, M.S. Failure mode and effect analysis improvement: A systematic literature review and future research agenda. Reliab. Eng. Syst. Saf., 2020, 199, 106885.
[http://dx.doi.org/10.1016/j.ress.2020.106885]
[14]
Prajapati, P.; Patel, A.; Shah, S. Application of DoE-based analytical QRM to development of the multipurpose RP-HPLC method for estimation of multiple FDC products of telmisartan using enhanced AQbD approach. J. Chromatogr. Sci., 2021, 60(6), 525-537.
[http://dx.doi.org/10.1093/chromsci/bmab123] [PMID: 34121125]
[15]
Prajapati, P.B.; Jayswal, K.; Shah, S.A. Application of quality risk assessment and DoE-based enhanced analytical quality by design approach to development of chromatography method for estimation of combined pharmaceutical dosage form of five drugs. J. Chromatogr. Sci., 2021, 59(8), 714-729.
[http://dx.doi.org/10.1093/chromsci/bmaa118] [PMID: 33352579]
[16]
Chaturvedi, P.K.; Joshi, K.H.; Chopra, S.; Tauro, S.J.; Prajapati, P.B. Pitfalls and opportunities in the execution of quality by design in analytical sciences. Curr. Pharm. Anal., 2023, 19(5), 399-412.
[http://dx.doi.org/10.2174/1573412919666230517141015]
[17]
The European Medicines Agency. Assessment report Daklinza; EMA/419836/2014; London, UK. , 2014.
[18]
Jagadabi, V. Nagendra kumar, P.V.; Mahesh, K.; Pamidi, S.; Ramaprasad, L.A.; Nagaraju, D. A stability-indicating UPLC method for the determination of potential impurities and its mass by a new QDa mass detector in daclatasvir drug used to treat Hepatitis C infection. J. Chromatogr. Sci., 2019, 57(1), 44-53.
[http://dx.doi.org/10.1093/chromsci/bmy079] [PMID: 30169761]
[19]
Zaman, B.; Hassan, W. Development of stability indicating HPLC–UV method for determination of daclatasvir and characterization of forced degradation products. Chromatographia, 2018, 81(5), 785-797.
[http://dx.doi.org/10.1007/s10337-018-3503-7]
[20]
Baker, M.M.; El-Kafrawy, D.S.; Mahrous, M.S.; Belal, T.S. Validated stability-indicating HPLC-DAD method for determination of the recently approved hepatitis C antiviral agent daclatasvir. Ann. Pharm. Fr., 2017, 75(3), 176-184.
[http://dx.doi.org/10.1016/j.pharma.2016.12.005] [PMID: 28187879]
[21]
Gad, M.; Hassan, S.A.; Zaazaa, H.E.; Amer, S.M. Multivariate development and optimization of stability indicating method for determination of daclatasvir in presence of potential degradation products. Chromatographia, 2019, 82(11), 1641-1652.
[http://dx.doi.org/10.1007/s10337-019-03793-y]
[22]
Jiang, H.; Kandoussi, H.; Zeng, J.; Wang, J.; Demers, R.; Eley, T.; He, B.; Burrell, R.; Easter, J.; Kadiyala, P.; Pursley, J.; Cojocaru, L.; Baker, C.; Ryan, J.; Aubry, A.F.; Arnold, M.E. Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma. J. Pharm. Biomed. Anal., 2015, 107, 409-418.
[http://dx.doi.org/10.1016/j.jpba.2015.01.027] [PMID: 25676854]
[23]
Rezk, M.R.; Bendas, E.R.; Basalious, E.B.; Karim, I.A. Development and validation of sensitive and rapid UPLC–MS/MS method for quantitative determination of daclatasvir in human plasma: Application to a bioequivalence study. J. Pharm. Biomed. Anal., 2016, 128, 61-66.
[http://dx.doi.org/10.1016/j.jpba.2016.05.016] [PMID: 27232152]
[24]
Hassib, S.T.; Taha, E.A.; Elkady, E.F.; Barakat, G.H. Reversed-phase liquid chromatographic method for determination of daclatasvir dihydrochloride and study of its degradation behavior. Chromatographia, 2017, 80(7), 1101-1107.
[http://dx.doi.org/10.1007/s10337-017-3321-3]
[25]
Tol, T.; Tawde, H.; Gorad, S.; Jagdale, A.; Kulkarni, A.; Kasbale, A.; Desai, A.; Samanta, G. Optimization of a liquid chromatography method for the analysis of related substances in daclatasvir tablets using design of experiments integrated with the steepest ascent method and Monte Carlo simulation. J. Pharm. Biomed. Anal., 2020, 178, 112943.
[http://dx.doi.org/10.1016/j.jpba.2019.112943] [PMID: 31677954]
[26]
Huang, Y.; Su, B.N.; Marshall, J.; Miller, S.A. Forced oxidative degradation pathways of the imidazole moiety of daclatasvir. J. Pharm. Sci., 2019, 108(10), 3312-3318.
[http://dx.doi.org/10.1016/j.xphs.2019.05.022] [PMID: 31145924]
[27]
Barnet, K.; McGregor, P.; Martin, G.; LeBlond, D.; Weitzel, M.; Ermer, J.; Walfish, S.; Nethercote, P.; Gratzl, G.; Kovacs, E. In Analytical target profile: Structure and application throughout the analytical lifecycle. Pharmacop. Forum, 2016, 42(5), 7.
[28]
Saha, C.; Gupta, N.V.; Chandan, R.S. Development and validation of a UPLC-MS method for determination of atazanavir sulfate by the “analytical quality by design” approach. Acta Pharm., 2020, 70(1), 17-33.
[http://dx.doi.org/10.2478/acph-2020-0008] [PMID: 31677371]
[29]
The United State Pharmacopoeia . The United States Pharmacopoeial Convention Rockville. 2020.
[30]
Prajapati, P.; Gami, A.; Shah, S. Analytical quality risk management and DoE based development of robust chromatographic method for simultaneous estimation of tizanidine hydrochloride and nimesulide in their combined pharmaceutical dosage forms. SN Appl. Sci., 2020, 2(2), 293.
[http://dx.doi.org/10.1007/s42452-020-2066-z]
[31]
Bamberg, V.M. Optimization of analytical method for quantification of 5-methoxycanthin-6-one by factorial design and preliminary stability test. Int. J. Pharm. Sci. Res., 2021, 12(2), 889-896.
[32]
Kumar, L.; Sreenivasa Reddy, M.; Managuli, R.S.; Pai, K. G. Full factorial design for optimization, development and validation of HPLC method to determine valsartan in nanoparticles. Saudi Pharm. J., 2015, 23(5), 549-555.
[http://dx.doi.org/10.1016/j.jsps.2015.02.001] [PMID: 26594122]
[33]
Roshdy, A.; Elmansi, H.; Shalan, S.; El-Brashy, A. Factorial design-assisted reversed phase-high performance liquid chromatography method for simultaneous determination of fluconazole, itraconazole and terbinafine. R. Soc. Open Sci., 2021, 8(2), 202130.
[http://dx.doi.org/10.1098/rsos.202130] [PMID: 33972882]
[34]
Mansuri, A.; Desai, S. 32 factorial design for optimization of HPLC-UV method for quantification of gallic acid in lohasava and pippalyasava. Indian J. Pharmaceut. Edu. Res., 2019, 53(3s), s347-s355.
[http://dx.doi.org/10.5530/ijper.53.3s.105]
[35]
Rozet, E.; Lebrun, P.; Hubert, P.; Debrus, B.; Boulanger, B. Design Spaces for analytical methods. Trends Analyt. Chem., 2013, 42, 157-167.
[http://dx.doi.org/10.1016/j.trac.2012.09.007]
[36]
Prajapati, P.B.; Mistry, K.Y.; Shah, S.A. DoE-Based Analytical Failure Modes Critical Effect Analysis (AFMCEA) to a multipurpose-RP-HPLC method for the estimation of multiple FDC products of metformin hydrochloride using an analytical quality by design approach. J. AOAC Int., 2022, 105(4), 986-998.
[http://dx.doi.org/10.1093/jaoacint/qsac025] [PMID: 35176154]
[37]
Pawar, A.; Pandita, N. Application of the “Method Operable Design Region” (MODR) approach for the development of a UHPLC method for the assay and purity determination of risperidone in risperidone drug substance and other formulations. Biomed. Chromatogr., 2022, 36(10), e5433.
[http://dx.doi.org/10.1002/bmc.5433] [PMID: 35760414]
[38]
Tome, T. Žigart, N.; Časar, Z.; Obreza, A. Development and optimization of liquid chromatography analytical methods by using AQbD principles: Overview and recent advances. Org. Process Res. Dev., 2019, 23(9), 1784-1802.
[http://dx.doi.org/10.1021/acs.oprd.9b00238]
[39]
ICH Harmonized Tripartite Guideline Validation of Analytical Procedures. Text and Methodology Q2(R1)., 1994. Available From: https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf
[40]
Wasserman, H.H.; Stiller, K.; Floyd, M.B. The reactions of heterocyclic systems with singlet oxygen. Photosensitized oxygenation of imidazoles. Tetrahedron Lett., 1968, 9(29), 3277-3280.
[http://dx.doi.org/10.1016/S0040-4039(00)89546-5]
[41]
Seburg, R.A.; Ballard, J.M.; Hwang, T.L.; Sullivan, C.M. Photosensitized degradation of losartan potassium in an extemporaneous suspension formulation. J. Pharm. Biomed. Anal., 2006, 42(4), 411-422.
[http://dx.doi.org/10.1016/j.jpba.2006.04.030] [PMID: 16787732]
[42]
Ryang, H.S.; Foote, C.S. Chemistry of singlet oxygen. 31. Low-temperature nuclear magnetic resonance studies of dye-sensitized photooxygenation of imidazoles: Direct observation of unstable 2,5-endoperoxide intermediates. J. Am. Chem. Soc., 1979, 101(22), 6683-6687.
[http://dx.doi.org/10.1021/ja00516a033]

Rights & Permissions Print Cite
Article Metrics
23
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy